New Launch9 Jan 2024, 10:54 pm
Lupin Launches Bromfenac Ophthalmic Solution in the US Secures 180-Day Exclusivity
AI Summary
Lupin Limited, a leading pharmaceutical company, has launched Bromfenac Ophthalmic Solution, 0.07%, in the US, after receiving approval from the FDA. The company is eligible for 180-day exclusivity, and the product is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. with estimated annual sales of USD 182 million in the US.,
Key Highlights
- Lupin launches Bromfenac Ophthalmic Solution in the US
- Secures 180-day exclusivity
- Estimated annual sales of USD 182 million in the US